Patient reported outcomes following proton pencil beam scanning vs. passive scatter/uniform scanning for localized prostate cancer: Secondary analysis of PCG 001-09
Background: Although pencil beam scanning (PBS) is the most conformal method for proton beam therapy (PBT) delivery, it is unknown if outcomes differ compared to treatment with passive scatter/uniform scanning (PS/US). This analysis compares patient reported outcomes (PRO) changes following PBS and...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-05-01
|
Series: | Clinical and Translational Radiation Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405630820300161 |
id |
doaj-fb5699f1503b4a6e8d256d059d7b84f7 |
---|---|
record_format |
Article |
spelling |
doaj-fb5699f1503b4a6e8d256d059d7b84f72021-06-02T12:33:24ZengElsevierClinical and Translational Radiation Oncology2405-63082020-05-01225054Patient reported outcomes following proton pencil beam scanning vs. passive scatter/uniform scanning for localized prostate cancer: Secondary analysis of PCG 001-09Mark V. Mishra0Rahul Khairnar1Søren M. Bentzen2Gary Larson3Henry Tsai4Christopher Sinesi5Carlos Vargas6George Laramore7Carl Rossi8Lane Rosen9Kai Sun10William Hartsell11Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, United States; Corresponding author at: Department of Radiation Oncology, University of Maryland School of Medicine, 22 S. Greene Street, GGK 0101, Baltimore, MD 21201, United States.Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, United StatesDepartment of Epidemiology & Public Health, Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, United StatesProCure Proton Therapy Center, Oklahoma City, OK, United StatesProCure Proton Therapy Center, Somerset, NJ, United StatesHampton University Proton Therapy Institute, Hampton, VA, United StatesDepartment of Radiation Oncology, Mayo Clinic Arizona, Phoenix, AZ, United StatesUniversity of Washington, Department of Radiation Oncology, Seattle, WA, United StatesCalifornia Protons Cancer Therapy Center, San Diego, CA, United StatesWillis-Knighton Proton Therapy Center, Shreveport, LA, United StatesDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, United StatesNorthwestern Medicine Chicago Proton Center, Warrenville, IL, United StatesBackground: Although pencil beam scanning (PBS) is the most conformal method for proton beam therapy (PBT) delivery, it is unknown if outcomes differ compared to treatment with passive scatter/uniform scanning (PS/US). This analysis compares patient reported outcomes (PRO) changes following PBS and PS/US for prostate cancer (PC) in a prospective multicenter registry study. Methods: We evaluated PROs with the Expanded Prostate Cancer Index Composite (EPIC) instrument for men with localized PC enrolled in PCG 001-09 (NCT01255748). PROs were assessed at baseline and through 12 months of follow-up. We compared mean changes in EPIC scores, as well as the proportions of men experiencing a one- and two-fold minimally important difference (MID) in domain scores, between PBS and PS/US. Multivariate analyses (MVAs) were performed to further evaluate the association between proton modality and PRO changes. Results: Three-hundred-and-four men completed EPIC at baseline; 72 received PBS and 232 received PS/US. The average quality-of-life (QOL) declines from baseline through 12 months did not significantly differ between the two groups. The proportion of men reporting a 1-MID decline at 12 months for PBS and PS/US was 34.3% and 27.4%, respectively, for urinary QOL (P = 0.27); 40. 1% and 40.9% for bowel QOL (P = 0.36); and 30. 1% and 36.6% for sexual QOL (P = 0.94). Corresponding 2-MID declines for PBS and PS/US were observed in 26.9% and 13.2% of men for urinary QOL (P = 0.01), 35.3% and 29.1% for bowel QOL (P = 0.33); and 16.4% and 18.1% for sexual QOL (P = 0.76). The association between proton modality and 2-MID changes in urinary QOL at 12-months remained significant on MVA (P = 0.007). Conclusions: The results of this analysis show differences between PBS and PS/US with regards to two-fold MID changes in urinary function at 12 months, but no differences for average score declines over time. Future studies evaluating PRO measures between the two PBT modalities are warranted.http://www.sciencedirect.com/science/article/pii/S2405630820300161 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mark V. Mishra Rahul Khairnar Søren M. Bentzen Gary Larson Henry Tsai Christopher Sinesi Carlos Vargas George Laramore Carl Rossi Lane Rosen Kai Sun William Hartsell |
spellingShingle |
Mark V. Mishra Rahul Khairnar Søren M. Bentzen Gary Larson Henry Tsai Christopher Sinesi Carlos Vargas George Laramore Carl Rossi Lane Rosen Kai Sun William Hartsell Patient reported outcomes following proton pencil beam scanning vs. passive scatter/uniform scanning for localized prostate cancer: Secondary analysis of PCG 001-09 Clinical and Translational Radiation Oncology |
author_facet |
Mark V. Mishra Rahul Khairnar Søren M. Bentzen Gary Larson Henry Tsai Christopher Sinesi Carlos Vargas George Laramore Carl Rossi Lane Rosen Kai Sun William Hartsell |
author_sort |
Mark V. Mishra |
title |
Patient reported outcomes following proton pencil beam scanning vs. passive scatter/uniform scanning for localized prostate cancer: Secondary analysis of PCG 001-09 |
title_short |
Patient reported outcomes following proton pencil beam scanning vs. passive scatter/uniform scanning for localized prostate cancer: Secondary analysis of PCG 001-09 |
title_full |
Patient reported outcomes following proton pencil beam scanning vs. passive scatter/uniform scanning for localized prostate cancer: Secondary analysis of PCG 001-09 |
title_fullStr |
Patient reported outcomes following proton pencil beam scanning vs. passive scatter/uniform scanning for localized prostate cancer: Secondary analysis of PCG 001-09 |
title_full_unstemmed |
Patient reported outcomes following proton pencil beam scanning vs. passive scatter/uniform scanning for localized prostate cancer: Secondary analysis of PCG 001-09 |
title_sort |
patient reported outcomes following proton pencil beam scanning vs. passive scatter/uniform scanning for localized prostate cancer: secondary analysis of pcg 001-09 |
publisher |
Elsevier |
series |
Clinical and Translational Radiation Oncology |
issn |
2405-6308 |
publishDate |
2020-05-01 |
description |
Background: Although pencil beam scanning (PBS) is the most conformal method for proton beam therapy (PBT) delivery, it is unknown if outcomes differ compared to treatment with passive scatter/uniform scanning (PS/US). This analysis compares patient reported outcomes (PRO) changes following PBS and PS/US for prostate cancer (PC) in a prospective multicenter registry study. Methods: We evaluated PROs with the Expanded Prostate Cancer Index Composite (EPIC) instrument for men with localized PC enrolled in PCG 001-09 (NCT01255748). PROs were assessed at baseline and through 12 months of follow-up. We compared mean changes in EPIC scores, as well as the proportions of men experiencing a one- and two-fold minimally important difference (MID) in domain scores, between PBS and PS/US. Multivariate analyses (MVAs) were performed to further evaluate the association between proton modality and PRO changes. Results: Three-hundred-and-four men completed EPIC at baseline; 72 received PBS and 232 received PS/US. The average quality-of-life (QOL) declines from baseline through 12 months did not significantly differ between the two groups. The proportion of men reporting a 1-MID decline at 12 months for PBS and PS/US was 34.3% and 27.4%, respectively, for urinary QOL (P = 0.27); 40. 1% and 40.9% for bowel QOL (P = 0.36); and 30. 1% and 36.6% for sexual QOL (P = 0.94). Corresponding 2-MID declines for PBS and PS/US were observed in 26.9% and 13.2% of men for urinary QOL (P = 0.01), 35.3% and 29.1% for bowel QOL (P = 0.33); and 16.4% and 18.1% for sexual QOL (P = 0.76). The association between proton modality and 2-MID changes in urinary QOL at 12-months remained significant on MVA (P = 0.007). Conclusions: The results of this analysis show differences between PBS and PS/US with regards to two-fold MID changes in urinary function at 12 months, but no differences for average score declines over time. Future studies evaluating PRO measures between the two PBT modalities are warranted. |
url |
http://www.sciencedirect.com/science/article/pii/S2405630820300161 |
work_keys_str_mv |
AT markvmishra patientreportedoutcomesfollowingprotonpencilbeamscanningvspassivescatteruniformscanningforlocalizedprostatecancersecondaryanalysisofpcg00109 AT rahulkhairnar patientreportedoutcomesfollowingprotonpencilbeamscanningvspassivescatteruniformscanningforlocalizedprostatecancersecondaryanalysisofpcg00109 AT sørenmbentzen patientreportedoutcomesfollowingprotonpencilbeamscanningvspassivescatteruniformscanningforlocalizedprostatecancersecondaryanalysisofpcg00109 AT garylarson patientreportedoutcomesfollowingprotonpencilbeamscanningvspassivescatteruniformscanningforlocalizedprostatecancersecondaryanalysisofpcg00109 AT henrytsai patientreportedoutcomesfollowingprotonpencilbeamscanningvspassivescatteruniformscanningforlocalizedprostatecancersecondaryanalysisofpcg00109 AT christophersinesi patientreportedoutcomesfollowingprotonpencilbeamscanningvspassivescatteruniformscanningforlocalizedprostatecancersecondaryanalysisofpcg00109 AT carlosvargas patientreportedoutcomesfollowingprotonpencilbeamscanningvspassivescatteruniformscanningforlocalizedprostatecancersecondaryanalysisofpcg00109 AT georgelaramore patientreportedoutcomesfollowingprotonpencilbeamscanningvspassivescatteruniformscanningforlocalizedprostatecancersecondaryanalysisofpcg00109 AT carlrossi patientreportedoutcomesfollowingprotonpencilbeamscanningvspassivescatteruniformscanningforlocalizedprostatecancersecondaryanalysisofpcg00109 AT lanerosen patientreportedoutcomesfollowingprotonpencilbeamscanningvspassivescatteruniformscanningforlocalizedprostatecancersecondaryanalysisofpcg00109 AT kaisun patientreportedoutcomesfollowingprotonpencilbeamscanningvspassivescatteruniformscanningforlocalizedprostatecancersecondaryanalysisofpcg00109 AT williamhartsell patientreportedoutcomesfollowingprotonpencilbeamscanningvspassivescatteruniformscanningforlocalizedprostatecancersecondaryanalysisofpcg00109 |
_version_ |
1721404473059835904 |